Skip to main content
. 2013 Feb 1;33(2):e00019. doi: 10.1042/BSR20110124

Figure 4. Therapeutic effect of MSC–PEDF against intracranical U87MG glioma.

Figure 4

To assess the therapeutic effect of MSC–PEDF for intracranical U87MG glioma, mice were intravenously injected with MSC–PEDF 7 days after intracranial implantation of tumour cells, and intravenous injection of MSC or PBS as control groups. Intravenous injection of MSC–PEDF has more benefits on the survival of tumour-bearing mice than PBS and MSC–LacZ-treated groups (P<0.01).